Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113958
Status:
COMPLETED
Last Update Posted:
2013-05-13
First Post:
2005-06-10
Brief Title:
Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative KDOQI Levels
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Cinacalcet Open Label Study to Reach KDOQI Levels
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism HPT to KDOQI recommended targets in subjects with end stage renal disease ESRD receiving hemodialysis on bio-intact parathyroid hormone corrected serum calcium serum phosphorus and calcium phosphorus product
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None